April 11, 2024
Vyvdura (efgartigimod alfa + vorhyaluronidase alfa), a treatment for generalized myasthenia gravis (gMG) developed by argenx, will be available for self-injection as a key reimbursement panel approved on April 10 its addition to a list of products covered by related...read more